Abstract
There remain several key challenges to existing for Colorectal Cancer (CRC) therapy by intravenous route, mainly associated to the targeted delivery of drugs in the colon and/or tumor region as well as the systemic side effects reduction. 5-fluorouracil (5-FU) is one of the first-line chemotherapeutic drugs in the CRC therapy; however, it has short plasma half-life, unstable absorption in…